Changes in US stocks | Ventyx Biosciences (VTYX.US) surged 60%, and it is reported that LLY.US (LLY.US) spent $1 billion on the acquisition

The Zhitong Finance App learned that, according to reports, LLY.US (LLY.US) is in in-depth negotiations to acquire Ventyx Biosciences (VTYX.US) for more than 1 billion US dollars to expand its business in the field of immunology. As of press release, Ventyx shares rose 62.59% to $16.34 in US overnight trading. The San Diego-based biotech company, which focuses on developing drugs to treat inflammatory diseases such as Crohn's disease and rheumatoid arthritis, will increase its market value by $433.9 million at this price. Reports of the Ventyx acquisition come as the pharmaceutical industry prepares to attend the J.P. Morgan Healthcare Conference in San Francisco, which has always been a popular venue for M&A deals.

Eli Lilly said immunology is a key growth area, and the company hopes to further expand its business based on its tremendous success in the treatment of diabetes and obesity. These successes have attracted the attention of investors and patients. The company currently sells a variety of medications to treat inflammatory diseases such as arthritis and psoriasis, including Taltz, but Taltz's key patent protections will expire in the next few years.

Meanwhile, the company is seeking acquisitions to expand its product line. In 2024, the company acquired Morphic Therapeutics for $3.2 billion to obtain an experimental drug to treat inflammatory bowel disease. Additionally, the company spent $2.4 billion to acquire Dice Therapeutics, a company that develops oral psoriatic treatments.